Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines againstMycobacterium tuberculosis
Open Access
- 1 July 2009
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 16 (7), 1025-1032
- https://doi.org/10.1128/cvi.00067-09
Abstract
The development and characterization of new tuberculosis (TB) vaccines has been impeded by the lack of reproducible and reliable in vitro assays for measuring vaccine activity. In this study, we developed a murine in vitro mycobacterial growth inhibition assay for evaluating TB vaccines that directly assesses the capacity of immune splenocytes to control the growth of Mycobacterium tuberculosis within infected macrophages. Using this in vitro assay, protective immune responses induced by immunization with five different types of TB vaccine preparations (Mycobacterium bovis BCG, an attenuated M. tuberculosis mutant strain, a DNA vaccine, a modified vaccinia virus strain Ankara [MVA] construct expressing four TB antigens, and a TB fusion protein formulated in adjuvant) can be detected. Importantly, the levels of vaccine-induced mycobacterial growth-inhibitory responses seen in vitro after 1 week of coculture correlated with the protective immune responses detected in vivo at 28 days postchallenge in a mouse model of pulmonary tuberculosis. In addition, similar patterns of cytokine expression were evoked at day 7 of the in vitro culture by immune splenocytes taken from animals immunized with the different TB vaccines. Among the consistently upregulated cytokines detected in the immune cocultures are gamma interferon, growth differentiation factor 15, interleukin-21 (IL-21), IL-27, and tumor necrosis factor alpha. Overall, we have developed an in vitro functional assay that may be useful for screening and comparing new TB vaccine preparations, investigating vaccine-induced protective mechanisms, and assessing manufacturing issues, including product potency and stability.Keywords
This publication has 36 references indexed in Scilit:
- A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in miceVaccine, 2009
- Early Pulmonary Cytokine and Chemokine Responses in Mice Immunized with Three Different Vaccines againstMycobacterium tuberculosisDetermined by PCR ArrayClinical and Vaccine Immunology, 2009
- Innate Invariant NKT Cells Recognize Mycobacterium tuberculosis–Infected Macrophages, Produce Interferon-γ, and Kill Intracellular BacteriaPLoS Pathogens, 2008
- Influence ofMycobacterium bovisBCG Vaccination on Cellular Immune Response of Guinea Pigs Challenged withMycobacterium tuberculosisClinical and Vaccine Immunology, 2008
- Interleukin‐12 and Interleukin‐27 Regulate Macrophage Control ofMycobacterium tuberculosisThe Journal of Infectious Diseases, 2008
- Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel RecommendationsPLoS Medicine, 2008
- IL-21 and TGF-β are required for differentiation of human TH17 cellsNature, 2008
- Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosisJCI Insight, 2007
- Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiationNature Reviews Immunology, 2005
- Novel human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteriaImmunology Today, 1998